Table 2: Univariate and multivariate analysis for factors associated with development of active TB while receiving ART.

VariablesTB while receiving ARTUnadjustedAdjusted
Yes ()No ()OR (95% CI) valueOR (95% CI) value

Gender
Male24 (55.81)072 (20.69)
Female19 (44.19)276 (79.31)4.8 (2.5–9.3)<0.0012.9 (1.3–6.2)0.007
Age group
≥50 years07 (16.28)005 (16.67)
<50 years36 (83.72)290 (83.33)1.0 (0.4–2.2)0.949
Marital status
Single04 (09.30)050 (14.37)0.6 (0.2–1.7)0.368
Married21 (48.84)143 (41.09)1.4 (0.7–2.5)0.333
Divorced17 (39.53)095 (27.30)1.7 (0.9–3.3)0.166
Widowed01 (02.33)060 (17.24)0.1 (0.0–0.8)0.034
Occupation
Formal02 (04.65)023 (06.61)0.7 (0.2–3.0)0.622
Peasant06 (13.95)096 (27.59)0.4 (0.2–1.0)0.061
Petty business18 (41.86)110 (31.61)1.5 (0.8–2.9)0.179
Driver04 (09.30)008 (02.30)4.3 (1.2–15.0)0.0272.5 (0.4–13.3)0.294
Student02 (04.65)007 (02.01)2.3 (0.4–11.8)0.290
H/wife05 (11.63)036 (10.34)1.1 (0.4–3.0)0.796
Others06 (13.95)058 (19.54)0.7 (0.2–1.6)0.380
Nutrition status
Under WT14 (32.56)048 (13.79)3.0 (1.4–6.1)0.0021.4 (0.6–3.2)0.463
Normal WT21 (48.84)204 (58.62)0.7 (0.3–1.2)0.223
Over WT06 (13.95)064 (18.39)0.7 (0.3–1.8)0.476
Obese02 (03.23)053 (08.76)0.4 (0.1–2.0)0.329
WHO stage
3 and 431 (72.09)148 (42.53)
1 and 212 (27.91)200 (57.47)3.5 (1.7–7.0)<0.0012.4 (1.0–5.2)0.029
Baseline CD4
<200 cells/µl35 (81.40)094 (27.01)
≥200 cells/µl08 (18.60)254 (72.99)11.8 (5.2–26.4)<0.0019.1 (3.9–21.0)<0.001
Anemia
Yes22 (51.16)167 (47.99)
No21 (48.84)181 (52.01)1.1 (0.6–2.1)0.694
IPT use
No39 (90.70)249 (71.55)
Yes04 (09.30)099 (28.45)3.8 (1.3–11.1)0.0123.1 (1.0–9.4)0.05
ART regimen
TDF/3TC/EFV39 (90.70)336 (96.55)0.3 (0.1–1.1)0.080
AZT/3TC/EFV02 (04.65)004 (01.15)4.1 (0.7–23.6)0.104
AZT/3TC/NVP02 (04.65)008 (02.30)2.0 (0.4–10.1)0.367

ART: antiretroviral therapy; AZT: zidovudine; CI: confidence interval; CD4: cluster of differentiation 4; EFV: efavirenz; 3TC: lamivudine; H/wife: housewife; IPT: isoniazid preventive therapy; NVP: nevirapine; TDF: tenofovir; WT: weight.